Rhabdomyolysis daptomycin

Ka ny A, Dibadj, K, Weiner ID. Rhabdomyolysis and acute renal iluFe in a patient treated with daptomycin. J Antimicrob Chemother (2006) 57,578-9... 

Sbrana F, Di Paolo A, Pasanisi EM, Tagliaferri E, Arvia C, Puntoni M, Leonildi A, Bigazzi F, Danes R, Rovai D, Tasdni C, Menichetti F. Administration interval and daptomycin toxicity a case report of rhabdomyolysis. J Che-mother 2010 22(6) 434-5. 

Musculoskeletal Rhabdomyolysis and acute renal failure have been associated with daptomycin 7.2 mg/kg/day in a patient taking simvastatin 80 mg/day [199 ]. After 16 days creatine kinase activity rose to 8995 IU/1 and there was weakness and diffuse aching in the forearms, with deterioration of renal function. Daptomycin was switched to line-zolid and ciprofloxacin and the creatine kinase activity normalized. 

In a retrospective multicenter study of daptomycin in doses up to 6 mg/kg (n = 188) or over 6 mg/kg (n = 139). 10% in both groups had adverse reactions that were possibly related to daptomycin 15 had increased creatine kinase activity and two had rhabdomyolysis, both of whom had normal renal function and were receiving 4 mg/kg/day [202 ]. 

Odero RO, Cleveland KO, Gelfand MS. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase... 

A randomised, open-label, controlled trial of daptomycin to treat osteomyelitis associated with prosthetic devices revealed increases in CPK levels in 16% of those treated with 6mg/kg, and 21.7% of those treated with 8mg/kg. Daptomycin was given for between 6 and 8 weeks [148 ]. Similarly, a retrospective analysis of the use of daptomycin (4-6mg/kg) for complicated skin and soft-tissue infections with or without associated bacteraemia revealed a favourable safety profile. The most common adverse event reported was elevation of blood CPK [149 ]. A similar retrospective analysis investigating the safety of prolonged (>14days) daptomycin in 2263 patients reported increased blood CPK, nausea, diarrhoea, vomiting, thrombocytopenia, rash, pyrexia and increased blood creatinine at a rate of between 0.1% and 2.2% [150 ]. In contrast to this, a retrospective study assessed the safety of co-administration of daptomycin with statins. There was no significant increase in rhabdomyolysis with the combination [ISl ]. 

Musculoskeletal Rhabdomyolysis was reported in a male patient receiving concomitant RBV, pegylated interferon and daptomycin [100 ]. Proximal myalgia and weakness developed in the patient who was receiving longterm treatment for chronic hepatitis C. There was clinical improvement and reduction in creatine phosphokinase gradually over 10 days with hydration after all three drugs were stopped. 

Colomba C, Rubino R, Siracusa L, Mazzola G, Titone L. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon a-2b and ribavirin in a patient with hepatitis C. J Antimicrob Chemother 2012 67(l) 249-50. 

---